Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Reichardt et al.|The Lancet|2012Cited by 1.4k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal TumorsGeorge D. Demetri, Jeffrey D. Wayne, Margaret von Mehren et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 1.2k
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyMargaret von Mehren, Mary Anne Bergman|Journal of the National Comprehensive Cancer Network|2022Cited by 1.1k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyMargaret von Mehren, Jillian L. Scavone, R. Lor Randall et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 733
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice GuidelinesGeorge D. Demetri, John Zalcberg, Robert S. Benjamin et al.|Journal of the National Comprehensive Cancer Network|2007Cited by 636